FHI or CNS: Which Is the Better Value Stock Right Now?

Zacks research identifies Federated Hermes (FHI) as the superior value stock over Cohen & Steers Inc (CNS) within the Financial - Investment Management sector. FHI holds a Zacks Rank #2 (Buy) and a 'B' Value Grade, significantly outperforming CNS which has a Zacks Rank #3 (Hold) and an 'F' Value Grade. This assessment is driven by FHI's more favorable valuation metrics, including a forward P/E of 11.82 versus CNS's 24.30 and a PEG ratio of 0.70 compared to CNS's 2.50, indicating a stronger earnings outlook and better relative undervaluation.

Analysis

A comparative analysis between Federated Hermes (FHI) and Cohen & Steers (CNS) positions FHI as the superior value opportunity within the Financial Investment Management sector. This conclusion is supported by a robust set of quantitative metrics and proprietary ratings. FHI holds a Zacks Rank of #2 (Buy), indicating an improving earnings outlook driven by positive estimate revisions, whereas CNS is rated #3 (Hold). On a valuation basis, FHI appears significantly undervalued relative to CNS. FHI's forward P/E ratio is 11.82, less than half of CNS's 24.30. Furthermore, FHI's PEG ratio of 0.70 suggests its stock price is low relative to its expected earnings growth, a sharp contrast to CNS's PEG of 2.50. The disparity extends to book value, with FHI's P/B ratio at 3.7 compared to 6.96 for CNS. These factors culminate in FHI earning a 'B' grade for Value in the Zacks Style Score system, while CNS receives a failing 'F' grade, reinforcing FHI's standing as the more attractive option for value-focused investors.

Key Decisions for Investors

• Investors seeking value exposure in the investment management space should consider Federated Hermes (FHI) due to its strong Buy-equivalent rating and compelling valuation metrics, including a PEG ratio below 1.0.
• Holders of Cohen & Steers (CNS) should be cautious of its high valuation multiples, particularly a forward P/E of 24.30 and a PEG of 2.50, which suggest the stock may be priced for perfection with limited upside for value-oriented portfolios.
• The analysis points towards a potential relative value opportunity; investors could investigate a long FHI position, given its positive earnings outlook and favorable valuation, while re-evaluating or reducing exposure to the comparatively expensive CNS.
• Monitor upcoming earnings estimate revisions for FHI, as continued positive momentum would further validate its #2 (Buy) rank and serve as a potential catalyst for the stock.